Andrew Guggenhime Sells 10,000 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the transaction, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This represents a 8.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $53.00, for a total transaction of $530,000.00.

Vaxcyte Trading Down 2.4%

Shares of NASDAQ PCVX opened at $56.96 on Tuesday. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00. The business has a 50 day simple moving average of $52.21 and a 200-day simple moving average of $53.47.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the company posted ($1.04) EPS. Research analysts predict that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in shares of Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after buying an additional 15,774 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Vaxcyte in the first quarter worth about $219,000. Caxton Associates LLP bought a new position in shares of Vaxcyte during the 1st quarter valued at about $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after buying an additional 41,034 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PCVX. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Vaxcyte currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.